F J Palella1, C Armon2, J S Chmiel3, J T Brooks4, R Hart2, K Lichtenstein5, R M Novak6, B Yangco7, K Wood2, M Durham4, K Buchacz4. 1. Feinberg School of Medicine, Northwestern University, Chicago, IL, USA f-palella@northwestern.edu. 2. Cerner Corporation, Kansas City, MO, USA. 3. Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 4. Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA. 5. Eisenhower Medical Center, Rancho Mirage, CA, USA. 6. Department of Medicine, University of Illinois, Chicago, IL, USA. 7. Infectious Disease Research Institute, Tampa, FL, USA.
Abstract
OBJECTIVES: We sought to evaluate associations between CD4 at ART initiation (AI), achieving CD4 >750 cells/mm(3) (CD4 >750), long-term immunological recovery and survival. METHODS: This was a prospective observational cohort study. We analysed data from ART-naive patients seen in 1996-2012 and followed ≥3 years after AI. We used Kaplan-Meier (KM) methods and log-rank tests to compare time to achieving CD4 >750 by CD4 at AI (CD4-AI); and Cox regression models and generalized estimating equations to identify factors associated with achieving CD4 >750 and mortality risk. RESULTS: Of 1327 patients, followed for a median of 7.9 years, >85% received ART for ≥75% of follow-up time; 64 died. KM estimates evaluating likelihood of CD4 >750 during 5 years of follow-up, stratified by CD4-AI <50, 50-199, 200-349, 350-499 and 500-750, were 20%, 25%, 56%, 80% and 87%, respectively (log-rank P < 0.001). In adjusted models, CD4-AI ≥200 (versus CD4-AI <200) was associated with achievement of CD4 >750 [adjusted HR (aHR) = 4.77]. Blacks were less likely than whites to achieve CD4 >750 (33% versus 49%, aHR = 0.77). Mortality rates decreased with increasing CD4-AI (P = 0.004 across CD4 strata for AIDS causes and P = 0.009 for non-AIDS death causes). Among decedents with CD4-AI ≥50, 56% of deaths were due to non-AIDS causes. CONCLUSIONS: Higher CD4-AI resulted in greater long-term CD4 gains, likelihood of achieving CD4 >750, longer survival and decreased mortality regardless of cause. Over 80% of persons with CD4-AI ≥350 achieved CD4 >750 by 4 years while 75% of persons with CD4-AI <200 did not. These data confirm the hazards of delayed AI and support early AI.
OBJECTIVES: We sought to evaluate associations between CD4 at ART initiation (AI), achieving CD4 >750 cells/mm(3) (CD4 >750), long-term immunological recovery and survival. METHODS: This was a prospective observational cohort study. We analysed data from ART-naive patients seen in 1996-2012 and followed ≥3 years after AI. We used Kaplan-Meier (KM) methods and log-rank tests to compare time to achieving CD4 >750 by CD4 at AI (CD4-AI); and Cox regression models and generalized estimating equations to identify factors associated with achieving CD4 >750 and mortality risk. RESULTS: Of 1327 patients, followed for a median of 7.9 years, >85% received ART for ≥75% of follow-up time; 64 died. KM estimates evaluating likelihood of CD4 >750 during 5 years of follow-up, stratified by CD4-AI <50, 50-199, 200-349, 350-499 and 500-750, were 20%, 25%, 56%, 80% and 87%, respectively (log-rank P < 0.001). In adjusted models, CD4-AI ≥200 (versus CD4-AI <200) was associated with achievement of CD4 >750 [adjusted HR (aHR) = 4.77]. Blacks were less likely than whites to achieve CD4 >750 (33% versus 49%, aHR = 0.77). Mortality rates decreased with increasing CD4-AI (P = 0.004 across CD4 strata for AIDS causes and P = 0.009 for non-AIDS death causes). Among decedents with CD4-AI ≥50, 56% of deaths were due to non-AIDS causes. CONCLUSIONS: Higher CD4-AI resulted in greater long-term CD4 gains, likelihood of achieving CD4 >750, longer survival and decreased mortality regardless of cause. Over 80% of persons with CD4-AI ≥350 achieved CD4 >750 by 4 years while 75% of persons with CD4-AI <200 did not. These data confirm the hazards of delayed AI and support early AI.
Authors: Marie R McCausland; Angélica Cruz-Lebrón; Heather A Pilch-Cooper; Scott Howell; Jeffrey M Albert; Young S Park; Alan D Levine Journal: AIDS Date: 2020-05-01 Impact factor: 4.177
Authors: Thibaut Davy-Mendez; Sonia Napravnik; Joseph J Eron; Stephen R Cole; David van Duin; David A Wohl; Brenna C Hogan; Keri N Althoff; Kelly A Gebo; Richard D Moore; Michael J Silverberg; Michael A Horberg; M John Gill; W Christopher Mathews; Marina B Klein; Jonathan A Colasanti; Timothy R Sterling; Angel M Mayor; Peter F Rebeiro; Kate Buchacz; Jun Li; Ni Gusti Ayu Nanditha; Jennifer E Thorne; Ank Nijhawan; Stephen A Berry Journal: J Infect Dis Date: 2020-12-26 Impact factor: 5.226
Authors: Baba M Musa; Musa A Garbati; Ibrahim M Nashabaru; Shehu M Yusuf; Aisha M Nalado; Daiyabu A Ibrahim; Melynda N Simmons; Muktar H Aliyu Journal: Int Health Date: 2016-12-09 Impact factor: 2.473
Authors: Alan Raymond Lifson; Sale Workneh; Abera Hailemichael; Richard Fleming MacLehose; Keith Joseph Horvath; Rose Hilk; Anne Redmond Sites; Tibebe Shenie Journal: J Int Assoc Provid AIDS Care Date: 2019 Jan-Dec
Authors: Alison G Abraham; Long Zhang; Keri Calkins; Adrienne Tin; Andrew Hoofnagle; Frank J Palella; Michelle M Estrella; Lisa P Jacobson; Mallory D Witt; Lawrence A Kingsley; Todd T Brown Journal: AIDS Date: 2018-05-15 Impact factor: 4.177
Authors: Ernest Ekong; Nicaise Ndembi; Prosper Okonkwo; Patrick Dakum; John Idoko; Bolanle Banigbe; James Okuma; Patricia Agaba; William Blattner; Clement Adebamowo; Manhattan Charurat Journal: AIDS Res Ther Date: 2020-02-17 Impact factor: 2.250